Eur Rev Med Pharmacol Sci 2019; 23 (22): 10101-10106

DOI: 10.26355/eurrev_201911_19579

Effects of IL-1β and IL-18 induced by NLRP3 inflammasome activation on myocardial reperfusion injury after PCI

Y.-J. Bai, Z.-G. Li, W.-H. Liu, D. Gao, P.-Y. Zhang, M. Liu

First School of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, P.R., China. peiyingzhangnzy@sina.com


OBJECTIVE: To investigate the effect of nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome in the serum levels of interleukin-1β (IL-1β) and interleukin-18 (IL-18) in patients with myocardial reperfusion injury after the percutaneous coronary intervention (PCI).

PATIENTS AND METHODS: Twenty healthy controls (control group) and forty patients (treatment group) were recruited in this study. The enzyme-linked immunosorbent assay (ELISA) was used to measure the serum levels of IL-1β and IL-18 at various time points in both the control and treatment groups. Data processing and analysis were performed using the Statistical Product and Service Solution (SPSS) 22.0 software (IBM Corp, Armonk, NY, USA). Pearson’s correlation coefficient test was applied in all data analyses. A difference was statistically significant when p<0.05.

RESULTS: The levels of IL-1β and IL-18 in the treatment group were significantly higher than those in the control group (p<0.05). The IL-1β level in the treatment group peaked at 0.5 h after PCI and then, gradually decreased. The multiple regression analysis showed that IL-1β level was positively correlated with levels of LDL-C and IL-18 (p<0.05, r=0.527 and 0.955 respectively), and negatively correlated with the HDL-C level (p<0.05, r=-0.34).

CONCLUSIONS: The levels of IL-1β and IL-18 significantly rose in patients with myocardial ischemia-reperfusion injury after PCI.

Free PDF Download

To cite this article

Y.-J. Bai, Z.-G. Li, W.-H. Liu, D. Gao, P.-Y. Zhang, M. Liu
Effects of IL-1β and IL-18 induced by NLRP3 inflammasome activation on myocardial reperfusion injury after PCI

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 22
Pages: 10101-10106
DOI: 10.26355/eurrev_201911_19579